Plain-English translation of NCT06401616 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atrial Fibrillation research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether patients with atrial fibrillation (an irregular heartbeat) who have already had surgery to close off a small pouch in their heart called the left atrial appendage can safely stop taking blood-thinning medication. The study will compare two groups: one that continues the medication and one that stops it. Researchers will track both groups to see if stopping the medication is safe or if it increases the risk of stroke.
The left atrial appendage closure surgery significantly reduces stroke risk in patients with irregular heartbeat, which raises the question of whether blood-thinning medication is still necessary afterward. Since this medication carries its own risks—including dangerous bleeding—doctors need clear evidence about whether patients can safely stop taking it after the surgery.
You likely qualify if…
You likely don't qualify if…
You will have a heart CT scan to confirm your appendage closure was successful. If it was, you will be randomly assigned to either continue taking your blood-thinning medication or stop it for the duration of the trial. The study will then follow you over time to monitor for any signs of stroke, blood clots, or serious bleeding, using information from your medical records and registry data.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
Denmark